A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

* Signed written informed consent before start of study-related assessments or procedures * Diagnosis of axSpA (either ankylosing spondylitis or non-radiographic axSpA) and fulfilling the Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axSpA * Participants aged ≥ 18 years * Disease duration \< 5 years * Participants must have a Baseline disease activity as defined by an ASDAS ≥ 2.1 or a Bath AS Disease Activity Index (BASDAI) ≥ 4 * NSAID-naive or not treated with the maximal recommended NSAID dose during the last 2 weeks prior to the Baseline visit * Participants must never have failed a NSAID taken at maximal recommended dose for 2 weeks or more.

* Contraindications for NSAIDs or tumor necrosis factor (TNF) blocker according to local labeling * If entering the study on concomitant NSAIDs, participants taking the maximal recommended dose during the last 2 weeks prior to the Baseline Visit or have failed or developed intolerance to a NSAID taken at maximal recommended dose for 2 weeks or more at any time * Prior exposure to any anti-TNF therapy; any biologic therapy with a potential therapeutic impact on SpA, or participant has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.